| Document |
Document Title |
|
WO/2023/234031A1 |
Provided is an expression regulator that is inexpensive and highly safe, and that particularly excels in an effect of regulating the expression of genes related to skin function–associated factors. This expression regulator contains ...
|
|
WO/2023/235433A1 |
Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitor compounds and compositions comprising such compounds. The compounds may have a structure according to Formula (I). Also disclosed are methods of...
|
|
WO/2023/234620A1 |
The present invention relates to a novel strain having resistance to methylglyoxal and activity to reduce advanced glycation end products (AGEs), and a composition including the strain. The strain and the composition not only have resist...
|
|
WO/2023/231996A1 |
The present invention relates to a non-solvated crystal, hydrate crystal, solvated crystal, eutectic crystal or salt-type crystal of a compound as represented by formula (I),
|
|
WO/2023/232130A1 |
Disclosed in the present invention are a heterocyclic compound as shown in formula (I) or a stereoisomer, deuterated compound, solvate, pharmaceutically acceptable salt, or co-crystal thereof and a pharmaceutical composition thereof, and...
|
|
WO/2023/234312A1 |
Antibody preparations for treating autoimmune-type diseases such as autoimmune diseases, allergic diseases, and kidney diseases in which autoimmunity is involved have been proposed, but the administration route thereof has been limited t...
|
|
WO/2023/234346A1 |
The present invention addresses the problem of providing: a solid preparation obtained by blending an antacid and one or more types of compound selected from the group consisting of loxoprofen and a salt thereof, said preparation being a...
|
|
WO/2023/227666A1 |
The present disclosure relates to a method of treating an acute inflammatory condition in a subject comprising administering to the subject a therapeutically effective amount of a pyrimidinone compound.
|
|
WO/2023/227033A1 |
The present invention provides an antibody or antigen-binding fragment thereof specifically binding to BDCA2, and a composition comprising the antibody or antigen-binding fragment thereof. The present invention further provides a nucleic...
|
|
WO/2023/229389A1 |
The present invention relates to a composition for prevention or treatment of inflammatory or autoimmune skin diseases. By specifically inhibiting the activity of skin-specific T cells, the composition of the present invention can effici...
|
|
WO/2023/227731A1 |
The present invention relates to a set of peptides, to compositions and kits comprising or allowing the expression of said peptides, as well as to uses thereof, in particular for preventing or treating pain in a subject in need thereof.
|
|
WO/2023/227695A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a ...
|
|
WO/2023/230468A1 |
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
|
|
WO/2023/228154A1 |
Provided herein are methods of treating a patient, such as a human patient, having inflammation or an inflammatory disease or a disease in which inflammation is present, such as cardiovascular or vascular endothelium inflammation, such a...
|
|
WO/2023/228766A1 |
According to the present invention, an oral solid formulation is coated with a rapid disintegration gel coating that contains an acidic substance, a carbonate, and a polymer that turns into a gel through contact with moisture. As a resul...
|
|
WO/2023/230002A1 |
Disclosed herein are NLRP3 inflammasome inhibitors and compositions thereof. Also disclosed herein are methods including administering a therapeutically effective amount of a composition comprising at least one NLRP3 inflammasome inhibit...
|
|
WO/2023/227106A1 |
The present invention provides a pharmaceutical composition of a nucleoside-derived compound, a preparation method therefor, and use thereof, and belongs to the field of medicines. The pharmaceutical composition comprises a compound SHEN...
|
|
WO/2023/227696A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a ...
|
|
WO/2023/227070A1 |
The present disclosure relates to a double-stranded ribonucleic acid for inhibiting C3 gene expression, a modifier, a conjugate, and a use thereof. Specifically, the present disclosure relates to a double-stranded ribonucleic acid, a dou...
|
|
WO/2023/227080A1 |
Provided are a PROTAC compound, a pharmaceutical composition containing same, and a preparation method therefor and the use thereof. The PROTAC compound has a structure as represented by formula (I), and can be used for treating BTK-rela...
|
|
WO/2023/230175A1 |
This disclosure relates to a composition comprising an anti-inflammatory agent and an analgesic agent for treating anal gland disease. In particular, the disclosure relates to a composition formulated as a spray or wipe.
|
|
WO/2023/229034A1 |
The present invention provides an FPR2 agonist. More specifically, the FPR2 agonist contains, as an active ingredient, outer membrane vesicles derived from at least one lactic acid bacterium selected from the group consisting of lactic a...
|
|
WO/2023/230375A1 |
The present disclosure provides methods of treating a neuropathophysiological condition in a patient in need thereof. The patient can be treated with an effective amount of a cannabinoid.
|
|
WO/2023/230577A1 |
The present disclosure relates to methods for the treatment of diseases or disorders (e.g, cancer) with mTOR inhibitors. Specifically, the disclosure relates to methods of treating a subject having a cancer by administering a particular ...
|
|
WO/2023/226789A1 |
Provided are a functionalized targeting formulation, a method for preparing same, and a use thereof. The functionalized targeting formulation comprises an amphiphilic polymer and a biological agent. The amphiphilic polymer comprises a mo...
|
|
WO/2023/227697A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a ...
|
|
WO/2023/227698A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a ...
|
|
WO/2023/227946A1 |
Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, disease...
|
|
WO/2023/222051A1 |
Provided in the present invention is the use of a macrophage migration inhibitory factor (MIF), RIPK1, an MIF inhibitor and an RIPK1 inhibitor in perioperative ischemic brain injuries. The present invention discloses the key functions of...
|
|
WO/2023/223951A1 |
The present invention addresses the problem of providing a medicine for treating cardiovascular disease associated with inflammation of the cardiovascular system related to IL-6 and/or IL-1β. The present invention relates to an IL-6 and...
|
|
WO/2023/224853A1 |
This invention provides certain piperidine compounds as AT2R antagonists, e.g., compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and X are as defined herein, pharmaceutical compositions thereof,...
|
|
WO/2023/221977A1 |
Disclosed in the present invention are a chondroitin sulfate biological polyamine compound, a preparation method therefor and use thereof. The present invention provides a chondroitin sulfate biological polyamine compound, which is a com...
|
|
WO/2023/223057A1 |
The invention relates to selected macrocyclic compounds, and their use in the treatment or prevention of diseases and disorders. In particular, though not exclusively, the invention relates to the use of selected macrocyclic compounds in...
|
|
WO/2023/223223A1 |
The present invention relates to a pharmaceutical composition for use in preventing and/or reducing hepatotoxicity induced by acetaminophen. Said pharmaceutical composition comprises a combination of acetaminophen and nefopam, as nefopam...
|
|
WO/2023/225107A1 |
This disclosure relates to uses of diroximel fumarate by pulmonary administration in the treatment, prevention, or reversal of fibrosis e.g., pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF). In certain embodiments, this disclosur...
|
|
WO/2023/221793A1 |
The present invention provides use of a phenolic acid derivative in treating ischemic stroke. Specifically, the present invention provides use of a compound represented by the following formula (I), or a pharmaceutically acceptable salt ...
|
|
WO/2023/225596A1 |
Disclosed herein is a method of treating migraine in patients with a history of inadequate response to prior migraine treatments comprising: selecting a patient who, for at least the past month: 1) has had 2 to 8 migraines per month, and...
|
|
WO/2023/225664A1 |
The disclosure herein provides lactam substituted imidazopyridazine compounds of Formula (I), (II), (II-a), (II-a), (III)¸ (IV)¸ (IV-a)¸ and (IV-b), or pharmaceutical compositions thereof, for the modulation of IL-17A. These compounds...
|
|
WO/2023/223244A1 |
The present invention relates to a nanoassembly formed by the self-assembly of a compound selected from compounds of formula (Ia): [Chem. 6], R representing an alkyl group; and compounds of formula (Ib): [Chem. 7], the compound of formul...
|
|
WO/2023/224465A1 |
The invention relates to an insect composition for use as a medicament, and for use in a method for the restoration, maintenance or improvement of intestinal immunity and/or intestinal homeostasis and/or intestinal tolerance against food...
|
|
WO/2023/224170A1 |
The present invention relates to a composition for preventing, alleviating or treating arthritis, comprising, as an active ingredient, an Achyranthes japonica Nakai root extract or pimaric acid and kaurenoic acid isolated therefrom, and ...
|
|
WO/2023/222938A1 |
The present invention relates to coordination compounds, specifically to lanthanide coordination compounds that are proven to be useful as anti-inflammatory agents. The present invention further relates to novel gadolinium coordination c...
|
|
WO/2023/225143A1 |
The subject invention relates to a therapeutic patch, its manufacture and use wherein the patch comprises: a fabric layer made of synthetic fibers stretchable in both directions along a substantially orthogonal transverse axis of the pat...
|
|
WO/2023/224426A1 |
The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases, comprising, as an active ingredient, mesenchymal stem cells with increased production of interleukin 10 by Lactobacillus sake...
|
|
WO/2023/224166A1 |
The present invention relates to an anti-inflammatory composition containing 5-hydroxymaltol, and a composition for preventing, ameliorating, or treating inflammatory diseases, and according to the present invention, 5-hydroxymaltol inhi...
|
|
WO/2023/221981A1 |
Taxamairin and analogs thereof useful in the treatment of inflammatory diseases or conditions, such as inflammatory bowel disease, pharmaceutical compositions including the same, and methods of use and preparation thereof.
|
|
WO/2023/225282A1 |
Methods and uses are disclosed for treating a subject suffering from a disorder selected from a liver disorder, Cushing's syndrome, or Cushing's Disease, cancer, an infection, an inflammatory condition, a cardiovascular, endocrine, or ki...
|
|
WO/2023/225413A1 |
Provided herein are pharmaceutical compositions, such as topical compositions, comprising carnosine and chondroitin sulfate. Also provided herein are methods of preparing the pharmaceutical compositions and methods of using the same for ...
|
|
WO/2023/224519A1 |
The invention relates to the field of medicine, pharmacology and the chemical and pharmaceutical industry, and more particularly to a novel crystalline form of N,N'-bis-[2-(1Н-imidazol-4-yl)ethyl]propanediamide and to a pharmaceutical c...
|
|
WO/2023/225001A1 |
The disclosure provides naphthyridines based on the ENPP1 modulators of Formula (I), (Ia), (Ib), (I-1), (I-1a), (I-1b), (I-2), (I-2a), (I-2b), or (Ic) and salts thereof, and their use for the modulation of ENPP1 activity.
|
